Gut Peptide Hormones: The Digestive Signaling Network
Peptide Hormones
30+ peptide hormones
The gastrointestinal tract produces more than 30 distinct peptide hormones, making it the largest endocrine organ in the human body.
Steinert et al., Physiological Reviews, 2017
Steinert et al., Physiological Reviews, 2017
View as imageThe gut is not just a tube that absorbs food. It is the largest endocrine organ in the body, producing more than 30 distinct peptide hormones from specialized enteroendocrine cells scattered along its length.[1] These gut peptide hormones coordinate digestion, signal satiety to the brain, regulate insulin release, control stomach acid, and modulate inflammation. The therapeutic exploitation of one of them, GLP-1, has produced the most commercially successful drug class in pharmaceutical history.
This article is the hub for RethinkPeptides' coverage of the body's peptide hormone systems. Each section below links to deeper coverage of specific hormones and systems: CCK and satiety, ghrelin and hunger, GLP-1 and GIP incretins, neuropeptides, adipokines, cardiovascular peptides, and the complete peptide hormone catalog.
Key Takeaways
- The gastrointestinal tract contains at least six types of enteroendocrine cells (G, I, S, K, L, D cells) producing peptide hormones that regulate digestion, appetite, and metabolism
- Ghrelin, discovered in 1999 by Kojima and Kangawa, is the only known circulating peptide that stimulates hunger; all other gut peptide hormones suppress appetite
- The incretin effect (GIP + GLP-1 released from K and L cells after eating) accounts for 50-70% of the insulin response to oral glucose
- A 2017 Steinert et al. review across 56,004 data points mapped how ghrelin, CCK, GLP-1, and PYY coordinate meal-by-meal energy balance through distinct timing and receptor pathways
- Bariatric surgery dramatically alters gut peptide profiles, with GLP-1, PYY, and CCK levels rising 3-10 fold, which may explain its metabolic effects beyond caloric restriction
- The enteroendocrine system in obesity shows altered hormone secretion patterns, with reduced postprandial GLP-1 and PYY responses in obese individuals compared to lean controls
Enteroendocrine cells: the gut's distributed hormone factory
Unlike traditional endocrine glands that cluster in a single organ (the thyroid, the adrenals), enteroendocrine cells are scattered individually across the epithelial lining of the entire gastrointestinal tract. They make up only about 1% of gut epithelial cells by number, yet collectively they produce a greater diversity of hormones than any other organ system.[3]
The major enteroendocrine cell types and their primary products:
| Cell Type | Location | Primary Hormone | Key Function |
|---|---|---|---|
| G cells | Stomach antrum, duodenum | Gastrin | Stimulates stomach acid secretion |
| D cells | Stomach, duodenum, pancreas | Somatostatin | Inhibits acid and hormone release |
| I cells | Duodenum, jejunum | CCK (cholecystokinin) | Gallbladder contraction, pancreatic enzymes, satiety |
| S cells | Duodenum | Secretin | Pancreatic bicarbonate secretion |
| K cells | Duodenum, jejunum | GIP | Incretin effect (insulin potentiation) |
| L cells | Ileum, colon | GLP-1, GLP-2, PYY | Incretin effect, satiety, intestinal growth |
| Mo cells | Duodenum, jejunum | Motilin | Gastric motility (migrating motor complex) |
| EC cells | Throughout GI tract | Serotonin (5-HT) | Motility, secretion, nausea signaling |
Recent research has complicated this neat taxonomy. Single-cell RNA sequencing reveals that enteroendocrine cells are more plastic than previously thought: individual cells can co-express multiple hormones, and their hormone profiles shift depending on location, diet, and metabolic state.[3] The L cell, for instance, produces GLP-1, GLP-2, PYY, and oxyntomodulin simultaneously from the same proglucagon gene.
The appetite hormones: ghrelin versus the satiety signals
The gut orchestrates appetite through a coordinated system of opposing signals. Before a meal, ghrelin rises. After a meal, CCK, GLP-1, and PYY rise while ghrelin falls. This push-pull system operates on different timescales and through distinct neural and endocrine pathways.
Ghrelin: the hunger signal
Ghrelin is the only circulating peptide hormone that stimulates appetite. Discovered in 1999 by Kojima and Kangawa in rat stomach tissue, ghrelin is a 28-amino-acid peptide with an unusual octanoyl modification on its third serine residue, which is required for binding to the growth hormone secretagogue receptor (GHS-R1a).[4]
Plasma ghrelin concentrations rise before meals and fall within an hour after eating. In fasting humans, ghrelin levels increase progressively over 1-3 days. Beyond hunger signaling, ghrelin stimulates growth hormone release, promotes gastric motility, and influences reward-related feeding behavior through receptors in the ventral tegmental area and nucleus accumbens. For more on ghrelin's broader roles, see Ghrelin: The Hunger Hormone That Rises Before Meals.
CCK: the first satiety peptide
Cholecystokinin was one of the first gut hormones identified and remains the best-characterized satiety signal. Released from I cells in the duodenum and jejunum within minutes of nutrient arrival (particularly fat and protein), CCK acts through two receptor subtypes: CCK-A (predominantly peripheral) and CCK-B (predominantly central).[5]
CCK reduces meal size primarily through vagal afferent signaling rather than circulating hormone levels. It also stimulates gallbladder contraction, pancreatic enzyme secretion, and gastric emptying delay. A 2016 review by Desai et al. detailed how CCK-induced satiety depends on the membrane composition of vagal afferent neurons, a mechanism that may be impaired in obesity.[6] For a deep dive into CCK, see CCK (Cholecystokinin): The First Satiety Peptide Discovered.
PYY: the ileal brake
Peptide YY (PYY) is released from L cells in the ileum and colon in proportion to caloric intake. Its active form, PYY(3-36), crosses the blood-brain barrier and binds to Y2 receptors in the arcuate nucleus of the hypothalamus, reducing NPY/AgRP neuron activity and suppressing appetite.[1]
PYY also mediates the "ileal brake," a feedback mechanism that slows gastric emptying and small intestinal transit when undigested nutrients reach the distal gut. This gives the proximal intestine more time to absorb nutrients, a reflex that becomes therapeutically relevant in bariatric surgery and conditions that alter gut transit.
Coordination across a meal
Steinert et al. published the most comprehensive review of gut hormone coordination in 2017 in Physiological Reviews, synthesizing data across ghrelin, CCK, GLP-1, and PYY.[1] Their analysis mapped the temporal sequence: CCK peaks first (within 15-30 minutes of eating), GLP-1 rises within 10-15 minutes and stays elevated for 2-3 hours, and PYY reaches its peak at 1-2 hours and remains elevated for up to 6 hours. Ghrelin suppression occurs within 30 minutes and recovers as PYY declines.
This staggered timing means that each hormone governs a different aspect of the feeding cycle. CCK controls meal size (how much you eat at this meal). GLP-1 modulates both insulin release and near-term satiety. PYY influences inter-meal intervals (how long until you eat again). Ghrelin initiates the next meal. The system is not redundant; it is sequential.
The incretins: GIP and GLP-1
The incretin effect, first described in the 1960s, refers to the observation that oral glucose stimulates roughly 2-3 times more insulin secretion than the same amount of glucose delivered intravenously. Two hormones account for this effect: glucose-dependent insulinotropic polypeptide (GIP, released from K cells) and glucagon-like peptide-1 (GLP-1, released from L cells).[7]
Together, GIP and GLP-1 account for an estimated 50-70% of the insulin response to oral glucose in healthy individuals. In type 2 diabetes, the incretin effect is diminished: GLP-1 secretion is modestly reduced, and the insulinotropic response to GIP is severely blunted.[8]
A 2023 review by Drucker and Holst traced the "expanding incretin universe" from basic physiology to the clinical success of GLP-1 receptor agonists and dual GIP/GLP-1 agonists like tirzepatide.[9] They note that native GLP-1 has a half-life of only 2-3 minutes due to rapid degradation by dipeptidyl peptidase-4 (DPP-4), which is why therapeutic GLP-1 analogs were engineered for resistance to this enzyme. The result: drugs like semaglutide maintain GLP-1 receptor activation for days rather than minutes.
GIP's role has been more controversial. While it is the quantitatively dominant incretin (responsible for more of the insulin response than GLP-1 in healthy people), its therapeutic utility was long questioned because its insulinotropic action is impaired in type 2 diabetes. The success of tirzepatide, which agonizes both GIP and GLP-1 receptors, has reignited interest in GIP biology.[10] A 2026 review by Rossi et al. highlights GIP's emerging role in inflammation modulation, a function distinct from its incretin activity.[11]
For more on the two incretins and their therapeutic significance, see GLP-1 and GIP: The Two Incretins and Why They Matter. For cardiovascular effects of GLP-1 drugs specifically, see GLP-1 Drugs and Heart Disease: What the Cardiovascular Trials Show.
The digestive coordinators: gastrin, secretin, and motilin
Three peptide hormones handle the mechanical and chemical logistics of digestion itself, working upstream of the appetite and metabolic hormones.
Gastrin is released from G cells in the stomach antrum when protein digestion products, stomach distension, or vagal nerve stimulation occur. It drives hydrochloric acid secretion from parietal cells and stimulates the growth of the gastric mucosa. Chronic gastrin elevation (as occurs with proton pump inhibitor use) has been studied for potential associations with gastric neoplasia, though the clinical relevance in standard PPI use remains debated.
Secretin holds a unique place in history: it was the first hormone ever identified, described by Bayliss and Starling in 1902. Released from S cells in the duodenal mucosa when acidic chyme enters from the stomach, secretin stimulates pancreatic bicarbonate secretion to neutralize the acid. It also inhibits gastric acid production, creating a negative feedback loop with gastrin.
Motilin drives the migrating motor complex (MMC), the cyclical pattern of gastrointestinal contractions that occurs between meals to sweep residual food, bacteria, and cellular debris through the gut. Motilin levels oscillate with approximately 90-minute periodicity during fasting. Erythromycin, an antibiotic, happens to be a motilin receptor agonist, which is why it is sometimes used off-label as a prokinetic agent.
Somatostatin: the master brake on gut hormone release
Somatostatin deserves special attention because it acts as an inhibitory regulator of nearly every other gut peptide hormone. Produced by D cells distributed throughout the stomach, duodenum, and pancreatic islets, somatostatin exists in two active forms: somatostatin-14 and somatostatin-28.
In the gut, somatostatin suppresses gastrin (reducing acid secretion), CCK (reducing gallbladder contraction and pancreatic enzyme release), secretin (reducing bicarbonate output), GIP and GLP-1 (attenuating the incretin effect), and motilin (slowing motility). It acts through five receptor subtypes (SSTR1-5) in a paracrine fashion, meaning it reaches its targets by diffusion through local tissue rather than through the bloodstream.
Somatostatin analogs (octreotide, lanreotide) are used clinically to treat neuroendocrine tumors, acromegaly, and variceal bleeding. In the context of gut peptide biology, somatostatin represents a negative feedback layer: when nutrient absorption is complete and hormone-driven digestive processes are no longer needed, D cell activation dampens the entire system.
How nutrients trigger hormone release
Enteroendocrine cells are chemosensors. They detect specific nutrients through receptors on their luminal surface and translate nutrient presence into hormone secretion.
Fat is the most potent stimulator of CCK release, acting through fatty acid receptors (GPR40, GPR120) on I cells. Protein digestion products (amino acids and small peptides) stimulate both gastrin and CCK through calcium-sensing receptors and peptide transporters (PEPT1). Glucose triggers GIP release from K cells through the sodium-glucose cotransporter SGLT1 and subsequent cell depolarization. Bile acids stimulate GLP-1 secretion from L cells through the TGR5 receptor, creating a link between bile acid metabolism and incretin signaling.
This nutrient-sensing specificity explains why different macronutrient compositions produce different hormonal profiles after a meal: a high-fat meal generates a strong CCK and PYY response, while a high-carbohydrate meal produces a larger GIP spike. Mixed meals activate the full hormonal cascade.
GLP-2 and intestinal repair
GLP-2 is the lesser-known sibling of GLP-1, co-secreted from the same L cells through processing of the same proglucagon precursor. While GLP-1 acts on appetite and insulin, GLP-2 acts on the intestine itself: it stimulates mucosal growth, enhances nutrient absorption, reduces intestinal permeability, and increases mesenteric blood flow.
Teduglutide, a DPP-4-resistant GLP-2 analog, is approved for short bowel syndrome, where it reduces the need for parenteral nutrition by promoting intestinal adaptation. The existence of GLP-2 illustrates a pattern: gut peptide hormones often have local trophic functions alongside their systemic endocrine roles.
Gut peptide hormones in obesity
Obesity alters the enteroendocrine system in measurable ways. Miedzybrodzka, Reimann, and Gribble reviewed the evidence in 2022, documenting reduced postprandial GLP-1 and PYY secretion in obese individuals compared to lean controls, blunted CCK-induced satiety signaling, and diminished ghrelin suppression after meals.[3]
Whether these changes cause obesity or result from it remains an open question. Animal models suggest that high-fat diets can directly impair enteroendocrine cell function and reduce L cell density in the distal gut. Human data is more ambiguous: some studies show normalization of gut hormone profiles after weight loss, while others find persistent alterations even after BMI reduction.
Bariatric surgery provides the most dramatic natural experiment. Roux-en-Y gastric bypass (RYGB) produces 3-10 fold increases in postprandial GLP-1 and PYY levels, driven by the rapid delivery of undigested nutrients to L cell-rich distal intestine.[1] These hormonal changes occur within days of surgery, before substantial weight loss, and are believed to contribute to the rapid resolution of type 2 diabetes seen after RYGB.
The gut-brain axis: how peptide signals reach the brain
Gut peptide hormones reach the brain through two primary routes: the vagus nerve and the bloodstream.
The vagal pathway is fast and direct. CCK, GLP-1, PYY, and ghrelin all activate receptors on vagal afferent nerve endings in the gut wall and portal vein. These signals travel via the vagus nerve to the nucleus tractus solitarius (NTS) in the brainstem, which relays them to the hypothalamus and other appetite-regulating centers. Vagal signaling is the dominant pathway for CCK's satiety effect; vagotomy abolishes CCK-induced meal termination.
The bloodstream pathway is slower but allows hormones to act directly on brain regions with an incomplete blood-brain barrier, particularly the area postrema and the median eminence adjacent to the arcuate nucleus. PYY(3-36) and ghrelin use this route to modulate hypothalamic appetite circuits. A 2007 review by Wren et al. in Gastroenterology mapped the neural circuits through which gut hormones influence feeding behavior, identifying the arcuate nucleus as a critical integration point where ghrelin (orexigenic) and PYY/GLP-1 (anorexigenic) signals converge on opposing neuronal populations.[12]
A 2026 review by Beutler in the Journal of Clinical Investigation examined GLP-1 physiology along the entire gut-brain axis, noting that pharmacological GLP-1 receptor agonists achieve their weight loss effects primarily through brain GLP-1 receptors rather than peripheral gut signaling, a distinction that matters for understanding both efficacy and side effects.[13]
Therapeutic applications beyond GLP-1
While GLP-1 receptor agonists dominate the commercial landscape, the broader gut peptide hormone system remains a rich source of therapeutic targets.
Dual and triple agonists. Tirzepatide (GIP/GLP-1 dual agonist) has demonstrated weight loss of 15-25% in clinical trials. Retatrutide, a triple agonist targeting GLP-1, GIP, and glucagon receptors, achieved up to 24% weight loss in phase 2 trials. These multi-agonist approaches attempt to replicate the coordinated hormonal response that bariatric surgery produces naturally.[14]
Oxyntomodulin and glucagon analogs. Oxyntomodulin, another proglucagon-derived peptide from L cells, activates both GLP-1 and glucagon receptors. Its dual action promotes satiety (via GLP-1R) while increasing energy expenditure (via glucagon R), a combination that pure GLP-1 agonists do not provide. Several oxyntomodulin analogs are in clinical development.
Ghrelin antagonism. Blocking ghrelin signaling to reduce hunger has been an appealing but elusive target. Ghrelin receptor antagonists and inverse agonists have shown modest effects in preclinical models, but none have succeeded in late-stage clinical trials, partly because the ghrelin system has redundant hunger-signaling pathways.
PYY analogs. Intranasal and subcutaneous PYY(3-36) preparations have reduced food intake in human studies, but the therapeutic window is narrow: doses high enough to suppress appetite consistently tend to cause nausea.
What remains uncertain
Several fundamental questions about gut peptide hormones lack clear answers.
Enteroendocrine cell plasticity. How quickly do enteroendocrine cells reprogram their hormone output in response to dietary changes, and does this plasticity contribute to the metabolic adaptation seen in yo-yo dieting? Single-cell studies suggest rapid reprogramming is possible, but the functional consequences are poorly quantified.
Inter-individual variation. Why do some individuals mount robust postprandial GLP-1 and PYY responses while others produce minimal increases? Genetics, microbiome composition, and prior dietary exposure all play roles, but no predictive model exists.
Microbiome interactions. Gut bacteria produce short-chain fatty acids and secondary bile acids that directly stimulate enteroendocrine cells. The extent to which the microbiome modulates appetite through gut peptide hormone secretion, rather than through other pathways, is under active investigation. See Bacteriocins: The Antimicrobial Peptides Made by Your Gut Bacteria for related coverage.
Long-term adaptation. Do chronic GLP-1 receptor agonist users develop compensatory changes in other gut peptide hormones? Early data suggests that PYY and ghrelin levels shift during long-term semaglutide treatment, but the clinical implications of these shifts are unknown.
Exercise and gut hormones. Physical activity alters gut peptide secretion in ways that are incompletely understood. Acute exercise suppresses ghrelin and transiently increases GLP-1 and PYY, which may partly explain exercise-induced appetite suppression. A 2025 study by Aukan et al. found that plasma concentrations of gastrointestinal hormones varied substantially between individuals after identical dietary challenges, with exercise history and body composition both influencing the magnitude of hormonal responses.[15]
Circadian regulation. Gut peptide hormone secretion follows circadian patterns independent of meal timing. Ghrelin shows a nocturnal peak, and GLP-1 responses to identical meals are larger in the morning than in the evening. Whether disrupting these rhythms through shift work or irregular eating schedules contributes to metabolic disease is a growing area of investigation.
The Bottom Line
The gastrointestinal tract produces more than 30 peptide hormones from specialized enteroendocrine cells, making it the body's largest endocrine organ. These hormones operate in a coordinated temporal sequence: ghrelin rises before meals to stimulate hunger, CCK signals meal termination within minutes, GLP-1 modulates insulin and short-term satiety, and PYY controls inter-meal intervals for hours. The incretin hormones GIP and GLP-1 account for 50-70% of the insulin response to oral glucose. Obesity disrupts this system, and bariatric surgery dramatically amplifies gut peptide responses. Therapeutic exploitation of these hormones, particularly GLP-1 and now GIP, has produced transformative drugs for diabetes and obesity, with multi-agonist approaches attempting to replicate the full hormonal symphony.